Cibc World Market Inc. Acquires New Shares in Dyne Therapeutics, Inc. $DYN

Cibc World Market Inc. acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, Holdings Channel reports. The firm acquired 68,766 shares of the company’s stock, valued at approximately $1,345,000.

Several other hedge funds have also recently bought and sold shares of DYN. Adage Capital Partners GP L.L.C. purchased a new position in Dyne Therapeutics in the 2nd quarter valued at approximately $30,378,000. Marshall Wace LLP increased its position in Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after buying an additional 2,565,570 shares in the last quarter. Vanguard Group Inc. increased its position in Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after buying an additional 2,109,257 shares in the last quarter. Vestal Point Capital LP increased its position in Dyne Therapeutics by 281.4% during the third quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company’s stock worth $35,104,000 after buying an additional 2,047,500 shares in the last quarter. Finally, Deep Track Capital LP purchased a new position in Dyne Therapeutics during the third quarter worth $25,300,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were acquired at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the acquisition, the director directly owned 24,500 shares of the company’s stock, valued at $415,030. This trade represents a 8.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John Cox sold 3,311 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $60,789.96. Following the sale, the chief executive officer owned 370,834 shares in the company, valued at $6,808,512.24. This trade represents a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 1,559,462 shares valued at $29,814,746. Company insiders own 9.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DYN. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Morgan Stanley dropped their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. HC Wainwright dropped their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Finally, Sanford C. Bernstein raised their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $35.00.

Dyne Therapeutics Price Performance

DYN stock opened at $17.92 on Wednesday. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The stock’s fifty day simple moving average is $18.26 and its 200-day simple moving average is $18.22. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -5.57 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the firm posted ($1.05) EPS. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.